Royal Bank of Canada
TGTX icon

Royal Bank of Canada’s TG Therapeutics TGTX Stock Holding History

Royal Bank of Canada’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Sell
37,252
-4,582
-11% -$137K ﹤0.01% 3458
2025
Q4 		$1.25M Sell
41,834
-414,391
-91% -$13.5M ﹤0.01% 3498
2025
Q3 		$16.5M Sell
456,225
-217,145
-32% -$7.15M ﹤0.01% 1798
2025
Q2 		$24.2M Buy
673,370
+597,678
+790% +$22.3M ﹤0.01% 1403
2025
Q1 		$2.98M Buy
75,692
+10,660
+16% +$359K ﹤0.01% 2647
2024
Q4 		$1.96M Sell
65,032
-23,863
-27% -$685K ﹤0.01% 3045
2024
Q3 		$2.08M Buy
88,895
+45,787
+106% +$1,000K ﹤0.01% 2970
2024
Q2 		$767K Buy
43,108
+17,243
+67% +$275K ﹤0.01% 3667
2024
Q1 		$395K Sell
25,865
-37,281
-59% -$594K ﹤0.01% 4137
2023
Q4 		$1.08M Buy
63,146
+20,945
+50% +$243K ﹤0.01% 3612
2023
Q3 		$353K Buy
42,201
+11,339
+37% +$158K ﹤0.01% 4314
2023
Q2 		$766K Sell
30,862
-32,792
-52% -$847K ﹤0.01% 3603
2023
Q1 		$957K Sell
63,654
-3,476
-5% -$52.8K ﹤0.01% 3376
2022
Q4 		$794K Buy
67,130
+40,758
+155% +$296K ﹤0.01% 3693
2022
Q3 		$156K Sell
26,372
-25,848
-49% -$170K ﹤0.01% 4967
2022
Q2 		$221K Sell
52,220
-49,200
-49% -$307K ﹤0.01% 4737
2022
Q1 		$964K Buy
101,420
+27,766
+38% +$321K ﹤0.01% 3677
2021
Q4 		$1.4M Buy
73,654
+23,823
+48% +$618K ﹤0.01% 3494
2021
Q3 		$1.66M Sell
49,831
-17,497
-26% -$541K ﹤0.01% 3237
2021
Q2 		$2.61M Sell
67,328
-25,864
-28% -$1.02M ﹤0.01% 2833
2021
Q1 		$4.49M Buy
93,192
+75,729
+434% +$3.64M ﹤0.01% 2322
2020
Q4 		$909K Buy
17,463
+9,195
+111% +$311K ﹤0.01% 3559
2020
Q3 		$222K Buy
8,268
+1,071
+15% +$24.6K ﹤0.01% 4473
2020
Q2 		$141K Buy
7,197
+2,169
+43% +$34.9K ﹤0.01% 4646
2020
Q1 		$50K Sell
5,028
-5,194
-51% -$65.6K ﹤0.01% 5166
2019
Q4 		$114K Sell
10,222
-1,513
-13% -$11.5K ﹤0.01% 5016
2019
Q3 		$66K Buy
11,735
+249
+2% +$1.74K ﹤0.01% 5008
2019
Q2 		$99K Sell
11,486
-169
-1% -$1.28K ﹤0.01% 4887
2019
Q1 		$94K Hold
11,655
– – ﹤0.01% 4811
2018
Q4 		$48K Buy
11,655
+2,470
+27% +$12.3K ﹤0.01% 5132
2018
Q3 		$52K Sell
9,185
-5,013
-35% -$57.3K ﹤0.01% 5221
2018
Q2 		$187K Buy
14,198
+6,764
+91% +$93K ﹤0.01% 4443
2018
Q1 		$106K Sell
7,434
-6,593
-47% -$84.3K ﹤0.01% 4674
2017
Q4 		$115K Buy
14,027
+8,686
+163% +$75.9K ﹤0.01% 4731
2017
Q3 		$63K Buy
5,341
+5,060
+1,801% +$57.6K ﹤0.01% 5287
2017
Q2 		$3K Sell
281
-2,044
-88% -$22.9K ﹤0.01% 6204
2017
Q1 		$26K Buy
2,325
+896
+63% +$6.43K ﹤0.01% 5494
2016
Q4 		$6K Buy
1,429
+1,343
+1,562% +$7.88K ﹤0.01% 6254
2016
Q3 		$1K Sell
86
-93
-52% -$598 ﹤0.01% 6305
2016
Q2 		$1K Buy
179
+159
+795% +$1.29K ﹤0.01% 6268
2016
Q1 		$0 Buy
20
+3
+18% +$26 ﹤0.01% 6629
2015
Q4 		$0 Sell
17
-1,224
-99% -$15.5K ﹤0.01% 6814
2015
Q3 		$12K Buy
1,241
+1,041
+521% +$15.5K ﹤0.01% 5813
2015
Q2 		$3K Hold
200
– – ﹤0.01% 6324
2015
Q1 		$3K Buy
+200
New +$3.03K ﹤0.01% 5858
2013
Q4 		– Sell
-320
Closed -$2K – 6133
2013
Q3 		$2K Buy
+320
New +$1.96K ﹤0.01% 5868

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada's TGTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its TG Therapeutics (TGTX) stake by 11% in Q1 2026, selling an estimated $137K and leaving 37,252 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

Royal Bank of Canada first reported a position in TGTX in Q3 2013 and has held it in 46 quarters since. The position peaked at $24.2M in Q2 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Royal Bank of Canada held 37,252 shares of TG Therapeutics worth $1.24M as of Q1 2026.
  • Royal Bank of Canada sold 4,582 TG Therapeutics shares in Q1 2026, an estimated $137K.
  • TG Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3458 holding.
  • Royal Bank of Canada first reported a position in TG Therapeutics in Q3 2013 and has held it in 46 quarters since.
  • Royal Bank of Canada's TG Therapeutics position peaked at $24.2M in Q2 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.